INDIANAPOLIS–In a deal worth at least $720 million, Eli Lilly and Company says it will supply the U.S. government up to 600,000 thousand doses of a drug for the treatment of mild to moderate COVID-19 in certain high-risk patients.
The agreement is conditional on Lilly getting Emergency Use Authorization for the drug, which is called bebtelovimab. That request has been submitted to the FDA.
The deal also provides for an option of 500,000 additional doses.
Bebtelovimab can be used to treat people 12 and older who have mild to moderate COVID-19 and are at high risk of a severe form of the disease or for whom other treatment options aren’t accessible or clinically appropriate. It is not authorized for hospitalized patients or those who need oxygen therapy.
- Pence: Trump Owes it to the American People to Debate
- NWS: Expect a Rainy Wednesday Across Indiana
- Pacers GM: Contract Extension Talks with Buddy Hield Are “At a Halt” But That Doesn’t Mean They’re Done
- FOUND: Momo the Monkey on the Loose: Indianapolis’ East Side on High Alert
- Murder Suspect Kevin Mason Captured
The Dangers of Brown Friday & How You Can Prepare for the Worst
Police: Woman Killed, Infant Hurt in Head-On Crash with Semi-Truck
Small Plane Crashes Near Shelbyville Airport, Two People Dead
Feds, Rush County Sheriff Search Home In Valerie Tindall's Disappearance
ISP: Truck Driver Killed After Exiting Vehicle
Fishers Marching Band Appears in 2023 Macy's Parade
Fitness Studios Say Holding Company Has Not Paid Employees
Indianapolis Firefighter Among More than 20 Arrested in Child Solicitation Sting